JPRN-C000000450已完成1 期
Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with oral fluorinated pyrimidine compound S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancer - Phase I/II study on combination therapy consisting of a fixed dose-rate infusion of gemcitabine with S-1 (FGS) in patients with gemcitabine-refractory advanced pancreatic cancer
ational Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology Division0 个研究点目标入组 40 人开始时间: 2006年7月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Regular use of fenitoin, warfarin or frucitocin 2)History of fluorinated pyrimidine use 3)Severe diarrhea 4)Severe mental disorder 5)Severe infection 6)Severe complication 7)Intestinal pneumonia or lung fibrosis 8)History of chest radiotherapy 9)Massive pleural or abdominal effusion 10)Symptomatic brain metastasis 11)History of other active malignancy 12)Pregnancy or the desire to preserve fecundity 13)Inadequate physical condition, as diagnosed by primary physician
研究者
相似试验
招募中
1 期
Phase 1 clinical study on the combination therapy of CHP-NY-ESO-1 cancer vaccine and Poly-ICLC for the treatment of patients with NY-ESO-1 expressing refractory esophageal cancerRefractory esophageal cancerJPRN-UMIN000007961Kyoto Prefectural University of Medicine18
尚未招募
不适用
Phase I and II trial of combination therapy using nab-Paclitaxel+Pertuzumab+Trastuzumab for HER2 positive metastatic breast cancermetastatic breast cancerJPRN-UMIN000035869The University of Tokushima Graduate School, Depertment of Thoracic, Endocrine surgery and Oncology, Institute of Health Bioscience30
已完成
1 期
Phase I Clinical Study on the Combination Therapy of CHP-NY-ESO-1 Cancer Vaccine and MIS416 for the Treatment of Patients with NY-ESO-1 expressing Refractory Urothelial or Prostate CancerJPRN-UMIN000005246Mie University Graduate School of Medicine12
已完成
不适用
A study to evaluate the safety and tolerability of doxorubicin and durvalumab, in patients with advanced soft tissue sarcoma.KCT0003577Yonsei University Health System, Severance Hospital45
已完成
2 期
Phase II study comparing combination therapy with carboplatin plus pemetrexed vs combination therapy with pemetrexed plus bevacizumab in chemo-naive elderly patients with advanced non-squamous non-small-cell lung cancer (HSR1402).advanced non-squamous non-small-cell lung cancerJPRN-UMIN000014302Hamamatsu Univ. School of Medicine64